The antigenic component of the hepatitis B vaccine is best described as

The antigenic component of the hepatitis B vaccine is best described as

• A. Live, attenuated virus.
• B. Inactivated virus.
• C. Cryptic antigen.
• D. Recombinant antigen.

Answer: (D)

The main idea is that the hepatitis B vaccine uses a recombinant protein as its antigen, not any form of infectious virus. The vaccine contains the hepatitis B surface antigen (HBsAg) produced by recombinant DNA techniques (typically in yeast). This purified protein self-assembles into virus-like particles that closely resemble the native surface of HBV, so the immune system makes antibodies against HBsAg without any risk of infection. That’s why it’s described as a recombinant antigen—a subunit vaccine generated by genetic engineering rather than a live, attenuated virus or an inactivated whole virus. The other options would involve whole infectious material or different, non-relevant antigen forms, which is not how this vaccine is designed.

The main idea is that the hepatitis B vaccine uses a recombinant protein as its antigen, not any form of infectious virus. The vaccine contains the hepatitis B surface antigen (HBsAg) produced by recombinant DNA techniques (typically in yeast). This purified protein self-assembles into virus-like particles that closely resemble the native surface of HBV, so the immune system makes antibodies against HBsAg without any risk of infection. That’s why it’s described as a recombinant antigen—a subunit vaccine generated by genetic engineering rather than a live, attenuated virus or an inactivated whole virus. The other options would involve whole infectious material or different, non-relevant antigen forms, which is not how this vaccine is designed.